Tumor-infiltrating immune cell types predicting recurrence-free survival in melanoma patients receiving adjuvant PD-1 inhibitor therapy.

Ladányi A, Fröhlich G, Hegyi B, Horváth P, Balatoni T

Open source

DOI
10.3389/fimmu.2026.1886388
Published
2026
Container
Frontiers in immunology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1886388,
  title = {Tumor-infiltrating immune cell types predicting recurrence-free survival in melanoma patients receiving adjuvant PD-1 inhibitor therapy.},
  author = {Ladányi A and Fröhlich G and Hegyi B and Horváth P and Balatoni T},
  year = {2026},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2026.1886388},
  url = {https://doi.org/10.3389/fimmu.2026.1886388}
}

RIS

TY  - JOUR
TI  - Tumor-infiltrating immune cell types predicting recurrence-free survival in melanoma patients receiving adjuvant PD-1 inhibitor therapy.
AU  - Ladányi A
AU  - Fröhlich G
AU  - Hegyi B
AU  - Horváth P
AU  - Balatoni T
PY  - 2026
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1886388
UR  - https://doi.org/10.3389/fimmu.2026.1886388
ER  - 

APA

A, L., G, F., B, H., P, H., & T, B. (2026). Tumor-infiltrating immune cell types predicting recurrence-free survival in melanoma patients receiving adjuvant PD-1 inhibitor therapy.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1886388

Source records